Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases
Erbagci, Z.ül.; Tuncel, A.A.; Erbagci, I.
Journal of Drugs in Dermatology Jdd 5(7): 668-671
2006
ISSN/ISBN: 1545-9616 PMID: 16865875 Document Number: 9976
Porokeratosis is a group of cutaneous disorders of keratinization characterized by a predisposition to malignant transformation. The condition, which may be associated with immune suppression, is usually resistant to therapy and has a high frequency of recurrence. Imiquimod, a potent topical immune response modifier with antiviral, antitumor, and immunoregulatory properties, is currently approved for the treatment of external anogenital warts and actinic keratosis. However, there have been also several reports demonstrating its efficacy in a variety of premalignant and malignant conditions. We report on 2 cases with immunosuppression-associated porokeratosis successfully treated with 5% topical imiquimod application.
Document emailed within 1 workday
